Therapeutic Potential of CRISPR/Cas9 Nuclear Scissors in the Modulation of microRNAs in Various Cancers: A Review
Cancer is leading cause of death around the world. There are many strategies have been planned to tackle the cancer progression but each has its own merits and demerits. The microRNA`s are controlling 60 percent human genome, have role in progressive timing, organogenesis, hematopoiesis, cell proliferation, apoptosis and possibly tumorgenesis by amplification or deletion of genes. There are many drugs like 5-fluorouracil (5-FU), Celecoxib and genistein were used to modulate the miRNA`s expression but their success rate remained least. The clustered regularly interspaced short palindromic repeat (CRISPR/Cas9) is emerging technology used to modulate the expression of miR-17, miR-200c, and miR-141 with 96 percent success rate. This review will provide us information about the potential therapeutic use of CRISPR/Cas9 against defaulted microRNA`s in the longstanding repression and beginning or inhibition of cancer.
Focus on Medical Sciences Journal is an open access Journal. Articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License available at http://creativecommons.org/licenses/by-nc/4.0/. For non-commercial purpose, the published materials in whole or in part may use, distribute, and reproduce with proper citations. Authors will retain copyright of their papers without restrictions